ArticleClinical epigenetics2025
FBLN2 promoter hypermethylation: a negative prognostic biomarker and anti-PD-1 response predictor in clear cell renal cell carcinoma via high-throughput CpG Island screening.
Article in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundClear cell renal cell carcinoma (ccRCC), with rising incidence globally, shows heterogeneous responses to immune checkpoint blockade (ICB). DNA methylation dysregulation impacts tumor immunity, necessitating predictive CpG methylation biomarkers for ICB efficacy.
methodsGenome-wide methylation profiling (TCGA/GEO) identified prognostic promoter CpG islands linked to CD8⁺ T cell infiltration. Single-CpG resolution analysis guided TaqMan probe design, validated in two independent cohorts: non-ICB (n = 335) for prognosis and ICB-treated (n = 45) for immunotherapy prediction.
resultsHigh-throughput methylation analysis identified hypermethylation at the FBLN2 promoter (chr3:13590414-13591008), which correlated with advanced tumor stage, higher grade, and poorer overall survival (OS) and progression-free survival (PFS). This locus exhibited significant associations with CD8⁺ T cell infiltration and IFNγ pathway activation. In the non-ICB cohort, validation using a 5-CpG TaqMan assay confirmed FBLN2 hypermethylation as an independent prognostic marker for both OS (HR = 3.45, P < 0.001) and PFS (HR = 2.43, P = 0.023). Subsequent IHC analysis of 74 tumor specimens demonstrated strong concordance between FBLN2 percent methylation ratio (PMR) and CD8⁺ T cell density (r = 0.62, P < 0.0001). In the anti-PD-1-treated cohort, high FBLN2 methylation was associated with a favorable immunotherapy response (Cohen's weighted Kappa = 0.607, P < 0.001) and predicted superior PFS (median 11.2 vs 3.4 months, HR = 0.35, P = 0.006), suggesting its potential as a novel predictive biomarker for ICB efficacy.
conclusionsFBLN2 promoter hypermethylation is a promising prognostic biomarker in ccRCC and a potential predictor of immunotherapy response. These findings warrant further investigation to validate its potential for enhancing personalized patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.